Insight Molecular Diagnostics Inc. (IMDX) Stock Analysis

Insight Molecular Diagnostics Inc. (IMDX) is a publicly traded company in the HEALTHCARE sector. It trades at $5.95, carries a market capitalization of $198.91M. This page summarizes the public market data, fundamentals, and frequently asked questions for IMDX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NASDAQ

Key Metrics

• Price: $5.95
• Market Cap: $198.91M
• EPS: $-1.51
• 52-Week High: $8.51
• 52-Week Low: $2.33

Market Sentiment

Insight Molecular Diagnostics Inc. currently has a Bullish sentiment score of 0.58.

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. (IMDX) is a leading precision diagnostics company headquartered in Irvine, California, focused on transforming the landscape of molecular testing to improve patient care. The company specializes in developing cutting-edge diagnostic solutions that target critical unmet needs in oncology, leveraging innovative technologies to provide accurate and timely testing results. With a strong commitment to enhancing disease detection and patient outcomes, IMDX is stra...

GNG Research Analysis

GNG Research scores Insight Molecular Diagnostics Inc. (IMDX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMDX.

Frequently Asked Questions

Does IMDX pay dividends?

Insight Molecular Diagnostics Inc. (IMDX) does not currently pay a regular dividend.

What is IMDX's market cap?

Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $198.91M with a current stock price of $5.95.